Estero Map 10 mg 20 tablets

Estero Map 10 mg 20 tablets

Compound:

Each p / o tablet contains:

Rosuvastatin – 10 mg.

Auxiliary components: lactose monohydrate, microcrystalline cellulose, povidone K, crospovidone, magnesium stearate, colloidal silicon dioxide, methocel E5, talc, titanium dioxide, yellow iron oxide dye, red iron oxide, black iron oxide.

Properties:

Rosuvastatin is a synthetic lipid-lowering agent from the statin group, an inhibitor of GMC-CoA reductase. It helps to reduce intracellular cholesterol and increase the activity of LDL receptors and, accordingly, accelerate the catabolism of LDL cholesterol (Xc).

Indications:

Treatment of hypercholesterolemia in adults with primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia) or mixed hypercholesterolemia (type IIb) as an adjunct to diet when diet and other non-drug treatments (exercise, weight loss) are inadequate. Homozygous familial hypercholesterolemia as an adjunct to diet and other cholesterol-lowering therapy, or when such therapy is not appropriate for the patient. To slow the progression of atherosclerosis as an adjunct to diet in patients who are indicated for therapy to reduce the concentration of total cholesterol and LDL-C. Primary prevention of major cardiovascular complications (stroke, heart attack) in adult patients without clinical signs of coronary artery disease, but with an increased risk of its development.

Dosage and administration:

Inside, swallow the tablet whole with water. The drug can be administered at any time of the day, regardless of food intake. Before starting therapy, the patient should begin to follow a standard hypocholesterolemic diet and continue to follow it during treatment. The dose of the drug should be selected individually depending on the goals of therapy. The recommended initial dose is 5 or 10 mg 1 time / day. If necessary, the dose may be increased after 4 weeks. Only patients with severe hypercholesterolemia and a high risk of cardiovascular complications who have not achieved the desired result of therapy when taking a dose of 20 mg can take a dose of 40 mg. Elderly patients do not require dose adjustment. In patients with mild or moderate renal insufficiency, dose adjustment is not required. For patients with moderate renal impairment, an initial dose of 5 mg is recommended. Patients predisposed to myopathy: when prescribing doses of 10 and 20 mg, the recommended initial dose is 5 mg.

Contraindications:

Children’s age up to 18 years; hypersensitivity to rosuvastatin or any of the components of the drug; liver disease in the active phase; severe renal dysfunction; simultaneous reception of cyclosporine; pregnancy and lactation.

Precautionary measures:

Use with caution in renal failure, hypothyroidism, personal or family history of hereditary muscle diseases and a previous history of muscle toxicity when using other HMG-CoA reductase inhibitors, in chronic alcoholism, in patients over the age of 65 years, with a history of liver disease, sepsis , arterial hypotension, during major surgical interventions, trauma, severe metabolic endocrine or electrolyte disorders, with uncontrolled epilepsy, in people of Asian origin (Chinese, Japanese). When using rosuvastatin at a dose of 40 mg, it is recommended to monitor indicators of kidney function. It is recommended to carry out the determination of indicators of liver function before the start of therapy and 3 months after the start of therapy. The use of rosuvastatin should be discontinued or the dose reduced if the level of serum transaminase activity is 3 times the upper limit of the norm.

Side effects:

Headache, myalgia, asthenia, constipation, dizziness, nausea, abdominal pain, diabetes mellitus; itching, rash and hives; myopathy, hypersensitivity reactions, pancreatitis; jaundice, hepatitis; arthralgia; memory loss.

Storage method:

Store at a temperature not exceeding 30C in a dry place out of the reach of children.

Package:

The cardboard pack contains 2 blisters of 10 p / o tablets each, paper instructions.